WVP
ACOR

Worth Venture Partners’s Acorda Therapeutics ACOR Stock Holding History

Worth Venture Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-305
Closed -$770K – 161
2017
Q1 		$770K Buy
305
+61
+25% +$176K 0.68% 29
2016
Q4 		$551K Buy
+244
New +$580K 0.59% 48

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Worth Venture Partners's ACOR Position: Q2 2017 in Review

Worth Venture Partners sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 305 shares — an estimated $770K sold.

Worth Venture Partners first reported a position in ACOR in Q4 2016 and held it in 2 quarters. The position peaked at $770K in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Worth Venture Partners reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Worth Venture Partners sold 305 Acorda Therapeutics shares in Q2 2017, an estimated $770K.
  • Worth Venture Partners first reported a position in Acorda Therapeutics in Q4 2016 and held it in 2 quarters.
  • Worth Venture Partners's Acorda Therapeutics position peaked at $770K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Worth Venture Partners's 13F filing for Q2 2017, filed 11 Aug 2017.